Max Chan

Jan 5, 2024 | onlinelibrary.wiley.com | Philip Chiu-Tsun Tang |Max Chan |Jeff Chung |Alex Chan

Graphical Abstract Macrophage–Myofibroblast Transition In article number 2302203, Philip Chiu-Tsun Tang, Max Kam-Kwan Chan, Patrick Ming-Kuen Tang, and co-workers, elucidated dynamics of cancer-associated fibroblast (CAF) with integrative bioinformatics at single-cell resolution, therefore unexpectedly identified the importance of a hematopoietic mediator RUNX1 (phosphorylated Runx1, red) for macrophage–myofibroblast transition (MMT) in lung cancer, which may represent a druggable target for...

Nov 15, 2023 | onlinelibrary.wiley.com | Philip Chiu-Tsun Tang |Max Chan |Jeff Chung |Alex Chan

1 Introduction Lung carcinoma is a major cause of death worldwide. There were 5422 new cases of lung cancer in 2020 and ranked as the top cause of cancer deaths in 2020 in Hong Kong (Hong Kong Cancer Registry). Surgery, chemotherapy, and radiotherapy have been the mainstays of treatment for decades.

Jul 19, 2023 | friendsofcancerresearch.org | Max Chan

On July 11, 2023, Friends of Cancer Research (Friends) hosted, “Establishing Evidence: New Advancements Using ctDNA”, a hybrid public meeting in Washington, DC. The meeting includes data readouts for two initiatives that support this roadmap. The first project was identified as a knowledge gap in the evidentiary roadmap exercise and includes data of baseline ctDNA levels across cancer types, stages, and assays.

Jun 14, 2023 | friendsofcancerresearch.org | Max Chan

Skip to content Friends of Cancer Research Search Navigation Toggle Search Close June 14, 2023 Share Tags Patient Advocate Newsletter

Jun 1, 2023 | friendsofcancerresearch.org | Max Chan

On Monday, May 22, Friends of Cancer Research (Friends) hosted a hybrid public meeting titled “The Next Generation of Cellular Therapies: A Blueprint to Accelerate Development.” This meeting built on Friends’ previous work on Cell & Gene Therapies and was the second of two meetings in 2023 to explore next steps in the field.